Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. MorphoSys AG
  6. News
  7. Summary
    MOR   DE0006632003

MORPHOSYS AG

(MOR)
  Report
Delayed Xetra  -  11:35:29 2023-01-27 am EST
18.15 EUR   +0.83%
01/25Biopharma, Tech Stocks Lead European Equities Slightly Lower
MT
01/24Pharma Stocks Weigh Down European Equities in Tuesday Trading
MT
01/19Pharma Stocks Weigh Down European Equities in Thursday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about MORPHOSYS AG
01/25Biopharma, Tech Stocks Lead European Equities Slightly Lower
MT
01/13European Equities Rise in Friday Trading, ADRs End Week Up 2%
MT
01/11Transcript : MorphoSys AG Presents at 41st Annual J.P. Morgan Healthcare Conf..
CI
01/09MorphoSys Expects Topline Data From Phase 3 Trial of Bone Marrow Cancer Therapy in Earl..
MT
01/09MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in ..
CI
01/09Morphosys Ag : MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofib..
EQ
01/06Morgan Stanley downgrades Morphosys to 'Underweight'.
DP
01/06MORPHOSYS : Downgraded to Sell by Morgan Stanley
MD
01/05Morphosys sales target for Monjuvi weighs on share price
DP
01/05MORPHOSYS : Sell rating from JP Morgan
MD
01/05Morphosys: 2023 only best-case growth for cancer drug Monjuvi
DP
01/05Morphosys sees only best-case growth for cancer drug Monjuvi in 2023
DP
01/05MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financ..
EQ
01/05Ad Hoc : MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 20..
EQ
01/04European Equities Continue Strong Start to 2023 in Wednesday Trading
MT
More most relevant news
All news about MORPHOSYS AG
01/25Biopharma, Tech Stocks Lead European Equities Slightly Lower
MT
01/24Pharma Stocks Weigh Down European Equities in Tuesday Trading
MT
01/19Pharma Stocks Weigh Down European Equities in Thursday Trading
MT
01/13European Equities Rise in Friday Trading, ADRs End Week Up 2%
MT
01/11Transcript : MorphoSys AG Presents at 41st Annual J.P. Morgan Healthcare Conf..
CI
01/11Pharma Stocks Pull European Equities Lower in Wednesday Trading
MT
01/09MorphoSys Expects Topline Data From Phase 3 Trial of Bone Marrow Cancer Therapy in Earl..
MT
01/09MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in ..
CI
01/09Morphosys Ag : MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofib..
EQ
01/06Morgan Stanley downgrades Morphosys to 'Underweight'.
DP
More news
News in other languages on MORPHOSYS AG
01/25Les valeurs biopharmaceutiques et technologiques entraînent les actions européennes en ..
01/24Les valeurs pharmaceutiques pèsent sur les actions européennes dans les échanges de mar..
01/23Pvr : MorphoSys AG: Veröffentlichung gemäß ž 40 Abs. 1 WpHG mit dem Ziel der europaweiten ..
01/23Pvr : MorphoSys AG: Veröffentlichung gemäß ž 40 Abs. 1 WpHG mit dem Ziel der europaweiten ..
01/19Les valeurs pharmaceutiques pèsent sur les actions européennes dans la négociation de j..
01/19Pvr : MorphoSys AG: Veröffentlichung gemäß ž 40 Abs. 1 WpHG mit dem Ziel der europaweiten ..
01/19Pvr : MorphoSys AG: Veröffentlichung gemäß ž 40 Abs. 1 WpHG mit dem Ziel der europaweiten ..
01/19Pvr : MorphoSys AG: Veröffentlichung gemäß ž 40 Abs. 1 WpHG mit dem Ziel der europaweiten ..
01/19Pvr : MorphoSys AG: Veröffentlichung gemäß ž 40 Abs. 1 WpHG mit dem Ziel der europaweiten ..
01/18Pvr : MorphoSys AG: Veröffentlichung gemäß ž 40 Abs. 1 WpHG mit dem Ziel der europaweiten ..
More news
Analyst Recommendations on MORPHOSYS AG
01/06Morgan Stanley downgrades Morphosys to 'Underweight'.
DP
01/06MORPHOSYS : Downgraded to Sell by Morgan Stanley
MD
01/05MORPHOSYS : Sell rating from JP Morgan
MD
01/03JPMorgan Downgrades MorphoSys to Underweight From Neutral, Price Target is $2.9
MT
01/03MORPHOSYS : JP Morgan downgrades from Neutral to Sell rating
MD
More recommendations
Press releases
01/09Morphosys Ag : MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofib..
EQ
01/05MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financ..
EQ
01/05Ad Hoc : MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 20..
EQ
2022InnoCare Announces Approval of Tafasitamab in Combination with Lenalidomide for the Tre..
AQ
2022Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
AQ
More press releases
Upcoming event on MORPHOSYS AG